lung cancer liver cancer
OSI Bid Likely to Rise as Astellas Seeks Cancer Sales (Update4)
March 9 (Bloomberg) — OSI Pharmaceuticals Inc .’s status as one of the few U.S. biotechnology companies with income from an approved cancer drug likely will drive up the price Tokyo-based Astellas Pharma Inc.
Cyberknife on the liver tumor
